title: Discussion. Treatment algorithm: managing rheumatoid arthritis.
authors.forename: D C
authors.initials: DC
authors.lastname: Calabrese
authors.forename: R
authors.initials: R
authors.lastname: Konop
authors.forename: E
authors.initials: E
authors.lastname: Cannon
authors.forename: T K
authors.initials: TK
authors.lastname: Maves
authors.forename: J J
authors.initials: JJ
authors.lastname: Casberg
authors.forename: L
authors.initials: L
authors.lastname: Meske
authors.forename: I C
authors.initials: IC
authors.lastname: Coleman
authors.forename: B I
authors.initials: BI
authors.lastname: Orland
authors.forename: M J
authors.initials: MJ
authors.lastname: Florentine
authors.forename: Y
authors.initials: Y
authors.lastname: Southwell
authors.forename: M R
authors.initials: MR
authors.lastname: Harris
authors.forename: D M
authors.initials: DM
authors.lastname: Yoder
mesh_terms: D000465:Algorithms; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D003669:Deductibles and Coinsurance; D019468:Disease Management; D016527:Drug Costs; D004359:Drug Therapy, Combination; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000077339:Leflunomide; D006278:Medicare; D008727:Methotrexate / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D010349:Patient Compliance; D011320:Primary Health Care; D011788:Quality of Life; D012219:Rheumatology; D014481:United States; D000078329:Workforce
chemical_list: D018501:Antirheumatic Agents; D007555:Isoxazoles; D000077339:Leflunomide; D008727:Methotrexate